Skip to content

Study · Observational study · n = 30 · 2024

4 results

[Post-stroke cognitive impairment in young patients].

Shchepankevich LA, Rerikh KV, Gribacheva IA, Popova TF, Taneeva EV, Tyazhelnikov NE, Sokolova DV, Boznyakov AV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2024

PMID39269301 (opens in a new tab)DOI10.17116/jnevro202412408192 (opens in a new tab)PepBankPUB-39269301
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In young patients after ischemic stroke, performance improved over time during Cortexin therapy, mainly in attention, short-term memory and multiple aspects of executive functions.

    In plain wordsIn young adults after stroke, attention, short-term memory and executive functions improved over time during Cortexin treatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseAttention, short-term memory and executive functions
    Study

    n = 30

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Over time, there was an improvement mainly in the areas of attention, short-term memory, and multiple aspects of executive functions.
    1 context sentence
    Summary · context
    The open prospective observational study included 30 patients from 18 to 45 years old with confirmed ischemic stroke in the carotid blood supply who received a course of treatment with Cortexin.
  2. 02HumanObservational studyEfficacy outcome

    In young stroke patients, MoCA scores improved significantly by the end of the second Cortexin course.

    In plain wordsYoung stroke patients had significantly better MoCA scores after the second Cortexin course.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseMoCA score at visit 4
    Study

    n = 30

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    MoCA score
    25.1 points
    baseline
    MoCA score
    28.4 points
    visit 4

    Source sentences

    Summary
    However, statistical significance for MoCA was achieved by the end of the second course of treatment with Cortexin (visit 4) - 28.4±1.3 points.
    2 context sentences
    Summary · context
    Thus, in the beginning of the study the MoCA test scores were 25.1±1.4 points.
    Summary · context
    The open prospective observational study included 30 patients from 18 to 45 years old with confirmed ischemic stroke in the carotid blood supply who received a course of treatment with Cortexin.
  3. 03HumanObservational studyEfficacy outcome

    In young stroke patients, delayed testing showed maintenance of cognitive functioning after Cortexin therapy.

    In plain wordsYoung stroke patients maintained their improved cognitive functioning at delayed testing after Cortexin therapy.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedDelayed cognitive score
    Study

    n = 30

    Comparator
    level achieved at visit 4
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Cognitive score
    28 points
    delayed testing

    Source sentences

    Summary
    Delayed neuropsychological testing showed encouraging results - the achieved level of cognitive functioning was maintained (28.0±1.1).
    1 context sentence
    Summary · context
    The open prospective observational study included 30 patients from 18 to 45 years old with confirmed ischemic stroke in the carotid blood supply who received a course of treatment with Cortexin.
  4. 04HumanObservational studyEfficacy outcome

    In young stroke patients, SF-36 scores improved significantly at visit 4 and remained improved at the fifth visit during Cortexin therapy.

    In plain wordsYoung stroke patients had significantly better quality of life at visit 4, with improvement maintained at the fifth visit.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseSF-36 quality of life
    Study

    n = 30

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Low quality of life scores persisted until the third visit; a significant improvement in SF-36 results was recorded at visit 4 and persisted with a positive trend at the fifth visit.
    1 context sentence
    Summary · context
    The open prospective observational study included 30 patients from 18 to 45 years old with confirmed ischemic stroke in the carotid blood supply who received a course of treatment with Cortexin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.